Does Rallies track congressional trades in INSM?

Yes. Rallies tracks politician and congressional stock disclosures for INSM, including reported purchases, sales, dates, owners, and trade amounts when available.

Is INSM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for INSM. It does not provide personalized investment advice.

INSM (Insmed) Stock Analysis - Politician Trades

Insmed (INSM) is a publicly traded Healthcare sector company. As of May 21, 2026, INSM trades at $107.56 with a market cap of $23.23B and a P/E ratio of -18.64. INSM moved +0.37% today. Year to date, INSM is -38.41%; over the trailing twelve months it is +57.51%. Its 52-week range spans $60.40 to $212.75. Analyst consensus is strong buy with an average price target of $203.20. Rallies surfaces INSM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded INSM stock?

Recent politician trading activity in INSM includes disclosures from Gilbert Cisneros, Gilbert Cisneros, Gilbert Cisneros, Josh Gottheimer, and Josh Gottheimer. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

INSM Key Metrics

Key financial metrics for INSM
Metric	Value
Price	$107.56
Market Cap	$23.23B
P/E Ratio	-18.64
EPS	$-5.74
Dividend Yield	0.00%
52-Week High	$212.75
52-Week Low	$60.40
Volume	2.61M
Avg Volume	0
Revenue (TTM)	$819.56M
Net Income	$-1.18B
Gross Margin	81.81%

Congressional Trades in INSM

Gilbert Cisneros sale INSM on Oct 3, 2025 (amount: $15.00K).
Gilbert Cisneros sale INSM on Sep 22, 2025 (amount: $15.00K).
Gilbert Cisneros sale INSM on Jul 7, 2025 (amount: $15.00K).
Josh Gottheimer purchase INSM on Jun 16, 2025 (amount: $15.00K) for Joint.
Josh Gottheimer sale INSM on Jun 21, 2024 (amount: $15.00K) for Joint.

Latest INSM News

Insmed Target Cut to $185 Signals 58.7% Upside Despite 23% Q1 Revenue Miss — May 13, 2026
Insmed slides after May 7 Q1 results show revenue miss despite reiterated guidance — May 7, 2026
Insmed Q1 Revenues Reach $306M with 44% BRINSUPRI Surge and TPIP Progress — May 7, 2026
Insmed and Ty Pennington Launch Suspect Bronchiectasis Campaign for 500,000 Patients — May 6, 2026
Insmed rises ahead of May 7 Q1 results, as pre-earnings positioning builds — May 4, 2026

Recent INSM Insider Trades

Flammer Martina M.D. sold 10.48K (~$1.23M) on May 14, 2026.
Bonstein Sara sold 8.27K (~$961.04K) on May 13, 2026.
Adsett Roger sold 5.84K (~$678.14K) on May 13, 2026.

INSM Analyst Consensus

16 analysts cover INSM: 0 strong buy, 16 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $203.20.

Common questions about INSM

Which politicians traded INSM stock?: Recent politician trading activity in INSM includes disclosures from Gilbert Cisneros, Gilbert Cisneros, Gilbert Cisneros, Josh Gottheimer, and Josh Gottheimer. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in INSM?: Yes. Rallies tracks politician and congressional stock disclosures for INSM, including reported purchases, sales, dates, owners, and trade amounts when available.
Is INSM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for INSM. It does not provide personalized investment advice.